Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium.
Bevacizumab biosimilar is supplied at a concentration of 25 mg/mL as a sterile, clear to slightly opalescent, colorless to pale brown solution, which contains 60 mg/mL α,α-trehalose dihydrate, 5.8 mg/mL sodium phosphate(monobasic, monohydrate),1.2 mg/mL sodium phosphate(dibasic, anhydrous), 0.4 mg/mL polysorbate 20, and Water for Injection.
Statement: this product is used for R&D only, not for clinical usage.
|
Name
|
Bevacizumab biosimilar
|
|
CAS NO.
|
216974-75-3
|
|
Type
|
Whole antibody
|
|
Source
|
Humanized (from mouse)
|
|
Target
|
VEGF-A
|
|
Clone
|
Monoclone
|
|
Formula
|
C6638H10160N1720O2108S44
|
|
Molecular Weight
|
149 kDa
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution in phosphate buffered saline
|
|
Grade Standard
|
Medicine Grade
|
|
Place of Origin
|
China (Mainland)
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
中文
